Content area
Full Text
Introduction of the rituximab biosimilar CT-P10 in the EU is predicted to result in significant budget savings and permit many more patients to access treatment. These were the findings of a CELLTRION Healthcarefunded study published in Advances in Therapy.
CT-P10 was recently approved in the EU for all indications approved for branded rituximab (MabTHera), including chronic lymphocytic leukaemia(CLL), non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis. A budget impact analysis model was used to evaluate the budgetary impact...